Clinical Trial Update: COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial update evaluating a COVID-19 vaccine booster in immunocompromised individuals with rheumatic diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Rheumatologic Disease
• Immunosuppression
• Overlap Connective Tissue Disease
• Rheumatoid Arthritis
• Scleroderma
• Systemic Lupus Erythematosus
• Systemic Sclerosis
• Systemic Vasculitis
• Undifferentiated Connective Tissue Diseases

Snippet

Sponsor: Paul R Fortin | Conditions: Rheumatoid Arthritis, Autoimmune Rheumatologic Disease | Phase 2, Phase 3 | Status: UNKNOWN